Pharmaceutical

J&J asserts its place in atopic dermatitis space with Yellow Jersey acquisition

J&J gains Phase II ready NM26, a bispecific antibody in development for the treatment of atopic dermatitis.

Jul 12, 2024 - 04:00
J&J asserts its place in atopic dermatitis space with Yellow Jersey acquisition
J&J gains Phase II ready NM26, a bispecific antibody in development for the treatment of atopic dermatitis.
Read the original article

Tags:

Previous Article

BARDA and Tiba Biotech link to develop ‘flu therapeutics

Next Article

Merz wins $185m bid for bankrupt Acorda assets and increases US workforce by 50%

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: The Apellis eye drug rebound accelerates. This time, it’s a competitor falling behind

STAT+: The Apellis eye drug rebound accelerates. This t...

Sep 20, 2023

ASCO 2024: Rakuten’s photoimmunotherapy and Keytruda combo shows efficacy in HNSCC

ASCO 2024: Rakuten’s photoimmunotherapy and Keytruda co...

May 29, 2024

STAT+: A controversial new study examines traditional Chinese medicine’s potential cardiac benefits

STAT+: A controversial new study examines traditional C...

Oct 24, 2023